ATE403653T1 - Pyridin-substituierte furanderivate als raf- kinase inhibitoren - Google Patents

Pyridin-substituierte furanderivate als raf- kinase inhibitoren

Info

Publication number
ATE403653T1
ATE403653T1 AT02777001T AT02777001T ATE403653T1 AT E403653 T1 ATE403653 T1 AT E403653T1 AT 02777001 T AT02777001 T AT 02777001T AT 02777001 T AT02777001 T AT 02777001T AT E403653 T1 ATE403653 T1 AT E403653T1
Authority
AT
Austria
Prior art keywords
sub
sup
kinase inhibitors
raf
pyridine
Prior art date
Application number
AT02777001T
Other languages
English (en)
Inventor
Andrew Kenneth Takle
David Matthew Wilson
David Kenneth Dean
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121485A external-priority patent/GB0121485D0/en
Priority claimed from GB0121493A external-priority patent/GB0121493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE403653T1 publication Critical patent/ATE403653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT02777001T 2001-09-05 2002-09-05 Pyridin-substituierte furanderivate als raf- kinase inhibitoren ATE403653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0121485A GB0121485D0 (en) 2001-09-05 2001-09-05 Compounds
GB0121493A GB0121493D0 (en) 2001-09-05 2001-09-05 Compounds

Publications (1)

Publication Number Publication Date
ATE403653T1 true ATE403653T1 (de) 2008-08-15

Family

ID=26246514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777001T ATE403653T1 (de) 2001-09-05 2002-09-05 Pyridin-substituierte furanderivate als raf- kinase inhibitoren

Country Status (6)

Country Link
US (1) US7375105B2 (de)
EP (1) EP1423383B1 (de)
AT (1) ATE403653T1 (de)
DE (1) DE60228098D1 (de)
ES (1) ES2309207T3 (de)
WO (1) WO2003022838A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395564A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
EP1263753B1 (de) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
US7827944B2 (en) * 2006-06-30 2010-11-09 Gm Global Technology Operations, Inc. System for controlling the response time of a hydraulic system
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (de) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und ihre verwendung
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2399921B1 (de) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und deren verwendung
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603214A4 (de) 2010-08-11 2013-12-18 Millennium Pharm Inc Heteroaryle und verwendungen davon
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
CN111285841A (zh) 2013-03-29 2020-06-16 雅沃科学有限责任公司 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物
WO2017189865A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
GB202015187D0 (en) 2020-09-25 2020-11-11 Sentinel Oncology Ltd A pharmaceutical salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735958A (en) 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
NZ505845A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
AU1596101A (en) 1999-11-12 2001-06-06 Merck & Co., Inc. Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
ATE318600T1 (de) 1999-11-12 2006-03-15 Merck & Co Inc Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
CA2395564A1 (en) * 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
JP2002037784A (ja) 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物

Also Published As

Publication number Publication date
EP1423383A1 (de) 2004-06-02
US7375105B2 (en) 2008-05-20
WO2003022838A8 (en) 2004-03-25
EP1423383B1 (de) 2008-08-06
ES2309207T3 (es) 2008-12-16
DE60228098D1 (de) 2008-09-18
WO2003022838A1 (en) 2003-03-20
US20040248896A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
EP1620411A4 (de) Hemmer der akt aktivität
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
ATE512957T1 (de) Hemmer der akt aktivität
DE602004023838D1 (de) Hemmer der akt aktivität
EP1737843A4 (de) Hemmer der akt aktivität
ATE381557T1 (de) Rho-kinase inhibitoren
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
TW200611907A (en) Fused heterocyclic compound
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
GB0005357D0 (en) Compounds
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties